tbuckley/cabot-search huggingface dataset:
<i>Annals</i> 2004–2005: A Peek Back and a Look Forward
Journal: Annals of Internal Medicine (2005)

Editorials21 June 2005Annals 2004–2005: A Peek Back and a Look ForwardThe EditorsThe EditorsSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-142-12_Part_1-200506210-00012 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail July marks the first issue of a new volume of Annals. The transition from volume 142 to 143 seems an appropriate time to reflect on the journal's health, review new features instituted over the past several months, mention developments on the horizon, and share a wish list for the types of articles that we would like to see in the months ahead.Vital SignsLike good clinicians, we begin by measuring our vital signs (Figure). Annals is in excellent health. Authors are submitting record numbers of manuscripts. We received 2671 submissions in 2004—more than in any year in the journal's ...References1. The Editors. Addressing the limitations of structured abstracts. Ann Intern Med. 2004;140:480-1. LinkGoogle Scholar2. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors [Editorial]. Ann Intern Med. 2004;141:477-8. [PMID: 15355883] LinkGoogle Scholar3. Sox HC. Improving patient care [Editorial]. Ann Intern Med. 2003;138:996. [PMID: 12809457] LinkGoogle Scholar4. Puhan MA, Steurer J, Bachmann LM, ter Riet G. Variability in diagnostic probability estimates [Letter]. Ann Intern Med. 2004;141:578-9. [PMID: 15466782] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Disclosures: None disclosed.Corresponding Author: Customer Service, American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 21 June 2005Volume 142, Issue 12_Part_1Page: 1016-1018KeywordsClinical trialsConflicts of interestInformation technologyPeer reviewPublic policyQuality improvementResearch laboratoriesSafetySystematic reviewsVital signs ePublished: 21 June 2005 Issue Published: 21 June 2005 Copyright & PermissionsCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Syk, c-Src, the αvβ3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption
Authors: Wei Zou, Hideki Kitaura, Jennifer Reeve, Fanxin Long, Victor L.J. Tybulewicz, Sanford J. Shattil, Mark H. Ginsberg, F. Patrick Ross, Steven L. Teitelbaum
Journal: The Journal of Experimental Medicine (2007)

I n this study, we establish that the tyrosine kinase Syk is essential for osteoclast function in vitro and in vivo.Syk -/-osteoclasts fail to organize their cytoskeleton, and, as such, their bone-resorptive capacity is arrested.This defect results in increased skeletal mass in Syk -/- embryos and dampened basal and stimulated bone resorption in chimeric mice whose osteoclasts lack the kinase.The skeletal impact of Syk defi ciency refl ects diminished activity of the mature osteoclast and not impaired differentiation.Syk regulates bone resorption by its inclusion with the αvβ3 integrin and c-Src in a signaling complex, which is generated only when αvβ3 is activated.Upon integrin occupancy, c-Src phosphorylates Syk.αvβ3-induced phosphorylation of Syk and the latter's capa city to associate with c-Src is mediated by the immunoreceptor tyrosine-based activation motif (ITAM) proteins Dap12 and FcRγ.Thus, in conjunction with ITAM-bearing proteins, Syk, c-Src, and αvβ3 represent an essential signaling complex in the bone-resorbing osteoclast, and, therefore, each is a candidate therapeutic target.
TRENDS IN STUDIES OF AMEBIASIS
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical Evaluation of a New Anticonvulsant, Sulthiame
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pity the FDA
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3593: PDK1 is a preferential metabolic target in glioblastoma
Authors: Maheedhara R. Guda, Swapna Asuthkar, Andrew J. Tsung, Kiran K. Velpula
Journal: Cancer Research (2019)

Abstract Glioblastoma (GBM), the most common adult primary malignant brain tumor, carries a high morbidity and mortality despite therapeutic advances. GBM’s progression is associated with a transition from oxidative phosphorylation to aerobic glycolysis as its main source of energy. Our laboratory recently confirmed that overexpression of pyruvate dehydrogenase kinase isoform 1 (PDK1) positively contributes to GBM progression. Here we report a novel role of mitofusin 1 (MFN1), a mitochondrial outer membrane GTPase that is a key regulator of mitochondrial fusion associated with glycolysis. We have shown that both PDK1 and MFN1 are highly co-expressed in glioblastoma patient specimens. Data obtained from The Cancer Genome Atlas demonstrated a positive correlation between PDK1 and MFN1 mRNA levels and the survival of GBM patients. The data obtained from the subtyped glioma stem cells corroborated with the datamining studies. To directly explore the potential MFN1-PDK1 interplay, we used CRISPR/Cas9 to suppress MFN1 expression in proneural, classical and mesenchymal subtypes of GBM stem cells (CSC). In another experiment, using ChIP assay, we showed that both PDK1 and MFN1 are under the transcriptional control of Myc oncogene. We present evidence that silencing MFN1 regulates altered metabolism in GBM CSC by increasing ROS levels, altering mitochondrial membrane potential, reduced lactate metabolites via NMR spectroscopy. Taken together, our results indicate that combined targeting of PDK1 and MFN1 shift Warburg effect towards oxidative phosphorylation, and may have increased therapeutic potential for glioblastoma patients. Citation Format: Maheedhara R. Guda, Swapna Asuthkar, Andrew J. Tsung, Kiran K. Velpula. PDK1 is a preferential metabolic target in glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3593.
The Expectation of Life Of the Consumptive After Sanatorium Treatment.
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
RIGHT ILIAC DISEASE.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dietary fiber and health. Council on Scientific Affairs
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cephaloglycin
Authors: Warren D. Johnson
Journal: JAMA (1968)

Cephaloglycin was evaluated in vitro and in the treatment of urinary tract infection. Over 90% of strains of Escherichia coli, Proteus mirabilis, and Klebsiella-Aerobacter were inhibited by concentrations of cephaloglycin achieved in the urine of patients receiving cephaloglycin as therapy for urinary tract infections. Peak serum concentrations of cephaloglycin inhibited all strains of group A streptococci and Diplococcus pneumoniae and some strains of Staphylococcus aureus, E coli, and p mirabilis. Twenty-three patients with urinary tract infection were treated with cephaloglycin. Most of the patients had structural abnormalities or chronic infection of the urinary tract. All patients were free of bacteriuria during therapy and 11 patients (48%) were abacteriuric one month after discontinuation of therapy. Diarrhea and eosinophilia were the only side effects noted and did not constitute a major problem.
Correction
Journal: Circulation (2007)

Event Rate in People With Coronary Disease" by Tonelli et al, which appeared in the October 25, 2005, issue (Circulation.2005;112:2627-2633), there was a minor error in the first paragraph of the Results section (p 2628).Currently, there is a discrepancy between Table 1 and the text; the table is correct.The text currently reads: "Serum phosphate ranged from 1.6 to 9.3 mg/dL (median, 3.3; interquartile range, 3.0 to 3.6; mean, 3.3Ϯ0.5 mg/dL), and 5.8% had serum phosphate levels outside the normal range of 2.5 to 4.5 mg/dL (hyperphosphatemia in 24 of 4127, hypophosphatemia in 215 of 4127)."The text should read: "Serum phosphate ranged from 1.6 to 9.3 mg/dL (median, 3.3; interquartile range, 3.0 to 3.6; mean, 3.3Ϯ0.5 mg/dL), and 3.8% had serum phosphate levels outside the normal range of 2.5 to 4.5 mg/dL (hyperphosphatemia in 24 of 4127, hypophosphatemia in 131 of 4127)."
Salicylate Action and Thyroidal Autonomy in Hyperthyroidism
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
From the NIH. Looking at menopause's role in osteoporosis
Authors: L. K. Doepel
Journal: JAMA (1985)

A recent large-scale epidemiologic study disputes the idea that menopause is a pivotal event in the development of osteoporosis leading to hip fractures in white women. The study shows that the hip fracture rate for white women starts a steep climb between ages 40 and 44—15 to 20 years earlier than generally believed. The incidence curve appears to continue to rise smoothly, with no apparent inflection (signifying an accelerated risk) around the time of menopause or thereafter. National Institute on Aging (Bethesda, Md) epidemiologists Jacob A. Brody, MD; Mary E. Farmer, MD, MPH; and Lon R. White, MD, MPH, presented their findings in a recent paper (<i>Am J Public Health</i>1984;74:1397-1398). According to their calculations, postponing the early rise in hip fracture incidence in white women by about five years would reduce overall hip fractures in this high-risk group by about 50%. The investigators suggest that the best way to
Cryofibrinogenemia
Authors: B. V. Jager
Journal: New England Journal of Medicine (1962)

RECENTLY, a sixty-four-year-old patient with lymphocytic leukemia of at least four years' duration was admitted to the St. Louis Veterans Administration Hospital with an acute illness that included ischemic necrosis of portions of the nose and toes, petechial hemorrhages in the skin, a severe hemorrhagic conjunctivitis and temporary loss of vision due to hemorrhage into the vitreous. Apart from leukocytosis, with an increased number of mature lymphocytes in the peripheral blood, the only pertinent laboratory abnormality was a large amount of cold-precipitable fibrinogen in the plasma. Unlike the usual cryofibrinogen, which is demonstrable only upon cooling of heparinized plasma, this . . .
SIMULTANEOUS IMMUNIZATIONS
Authors: A. C. McKean
Journal: JAMA (1934)

<h3>To the Editor:—</h3> I am interested in the communications on simultaneous immunizations inThe Journal, April 14, April 21 and June 2. I was in charge of a mobile clinic in Utah from June 1928 to April 1930 for the prevention of disease. During one year I gave more than 63,000 doses of vaccine. Experience proved that a person could be immunized against diphtheria, typhoid and smallpox at the same time without more reaction than one gets from vaccine given for only one disease, as nearly as I could judge. From April 1930 to September 1930 I served as director of the Utah County Health Unit at Provo, Utah. From September 1930 to July 1933 I served as director of Gila County Health Unit at Globe, Arizona. As deaths were occurring in Gila County from both typhoid and diphtheria and as smallpox was present, I gave simultaneous inoculations for all
Fatal acute Candida albicans bronchopneumonia. Report of a case
Authors: G. Ramirez
Journal: JAMA (1967)

THE ROLE of<i>Candida albicans</i>as a pathogenic organism of primary pulmonary disease has not been widely or completely accepted. Most of the reluctance arises from the fact that<i>C albicans</i>forms part of the normal flora of the mouth, and sputum cultures yield the organism in about 20% to 55% of normal individuals.<sup>1</sup>The organism has also been recovered from bronchial aspiration cultures in persons free of pulmonary disease.<sup>2</sup>The incidence of<i>C albicans</i>infections has increased especially in debilitated patients suffering from acute or chronic diseases or both, and in patients receiving treatment with broad-spectrum antibiotics or steroids.<sup>3</sup>Davis and Warren (1937) showed that<i>C albicans</i>could become pathogenic and cause fatal pulmonary candidiasis even without the action of the antibiotics.<sup>4</sup> The case to be reported here is a rare case of acute<i>C albicans</i>bronchopneumonia terminating in death and having no relation to
Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036. Methodological Issues
Authors: Bruce J. Trock, R. Jeffrey Karnes
Journal: European Urology (2017)
Urinary tract streptococcus group B infection in a 6-week-old infant
Authors: T. St-Laurent-Gagnon
Journal: JAMA (1978)

DURING recent years, an increased incidence of group B streptococcal infection has been reported in newborn infants. Two distinct types have been described.<sup>1,2</sup>The early-onset disease occurs within 24 hours after birth, is characterized by respiratory distress and septicemia, and is often fatal. The late-onset disease usually occurs between 1 and 12 weeks of age, presents as meningitis, and has a better prognosis. Asymptomatic bacteremia, osteomyelitis, septic arthritis, cellulitis, ethmoiditis, conjunctivitis, and pneumonia with empyema have also been reported.<sup>3</sup>Urine cultures have occasionally been reported as positive as an associated finding.<sup>4</sup>We report a case of lateonset urinary tract infection due to group B streptococcus, unassociated with septicemia or meningitis, and with unusually severe metabolic disorders and urinary tract structural anomalies. <h3>Report of a Case</h3> A 6-week-old boy was admitted to Ste-Justine Hospital because of anorexia and vomiting of two days' duration. His birth weight was 3,465
Anatomie der Hörrinde als Grundlage des physiologischen und pathologischen Geschehens der Gehörswahrnehmung
Authors: Iax Ll', Der De, Osterreichisch-Deutschen Wissenschaftshilfe
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal